CyclomicsSeq manuscript released!
16 July 2020 - We are happy to announce the publication of our preprint manuscript about CyclomicsSeq on biorxiv.org. The manuscript describes our technology for capturing, amplifying, and high-accuracy sequencing of short circulating tumor DNA molecules from patients with cancer. We have developed CyclomicsSeq to be compatible with any long-read DNA sequencer and have extensively tested the technology with Oxford Nanopore Flongle, MinION, and GridION systems. The use of the CyclomicsSeq consensus sequencing approach improves the quality of Oxford Nanopore sequencing by 60-fold, enabling the detection of rare mutations in the blood of cancer patients.
Cyclomics celebrates the signature of the collaboration agreement with UMCU
14 February 2020 - Cyclomics and University Medical Center Utrecht sign collaboration agreement
Following the licensing of liquid biopsy technology owned by the University Medical Center Utrecht (UMC Utrecht), Cyclomics and the UMC Utrecht have entered into a long-standing collaboration to strengthen the synergy between both parties further, and drive technological innovation and clinical evaluation of the CyclomicsSeq platform technology. The agreement is an essential milestone for Cyclomics and will accelerate the development of CyclomicsSeq for the assessment of treatment response and recurring disease for cancer patients.
Cyclomics mentioned on Nature Methods
30 July 2019 - Cyclomics mentioned in Nature Methods Technology Feature
The high-impact scientific journal Nature Methods has mentioned the Cyclomics founding team and technology in a recent article on Nanopore sequencing. The paper provides a historical overview of developments in Oxford Nanopore sequencing technology. One of the striking features of the Oxford Nanopore MinION instrument is the possibility of real-time and bedside diagnostics. These features are leveraged by the CyclomicsSeq technology, which provides a rapid and cost-effective assay for highly accurate detection of cancer mutations in blood.
Cyclomics highlighted on GenomeWeb
25 July 2019 - Cyclomics highlighted on GenomeWeb
A recent article on the most read genomics news website, has featured an interview with Cyclomics founders Alessio Marcozzi and Jeroen de Ridder. The news item - which can be read in full on GenomeWeb - provides a comprehensive overview of the CyclomicsSeq technology for detection of cancer mutations in circulating tumor DNA. The article further describes the current Cyclomics company structure as well as the plans towards clinical validation of CyclomicsSeq technology in the context of treatment response monitoring and detection of recurring disease in head and neck cancer patients.
Cyclomics at LC 2019
May 2019 - Cyclomics CEO Jeroen de Ridder presents at London Calling Nanopore user meeting.
During the yearly London Calling conference, organised by Oxford Nanopore Technologies, Cyclomics CEO Jeroen de Ridder reported on recent results obtained from their CyclomicsSeq platform. The London Calling conference is a yearly event, that attracts over 600 academic and industrial researchers, who use the Oxford Nanopore sequencing platform for applications ranging from genome research, pathogen detection, plant breeding and genetic diagnostics. Oxford Nanopore invited Cyclomics to present their recent work on clinical use of the CyclomicsSeq blood-based cancer detection platform, during a main stage plenary session.
Cyclomics gets the SME Instrument grant
March 2019 - Cyclomics receives the SME Instrument grant from the European Commission.
Based on a well-balanced proposal describing further developments to strengthen their business case, Cyclomics received 50,000 EUR in funding from the European Commission, as part of the SME Instruments phase 1 program. The project proposal was put together in a collaborative effort with Catalyze, an Amsterdam-based Life Sciences consultancy company....
Funds for clinical testing
October 2018 - Cyclomics obtains funding from the Oncode Institute for clinical testing of their technology.
In a combined effort, Cyclomics in collaboration with the University Medical Center Utrecht and the Netherlands Cancer Institute, will test their circulating tumor DNA sequencing technology for recurrence detection and treatment response monitoring in patients with advanced stage head and neck cancer. More than 90% of patient with HPV-negative head and neck cancer contain mutations in the TP53 gene. Cyclomics developed an highly-accurate assay to detect TP53 mutation in single ctDNA molecules....
Cyclomics obtains the Take-Off grant
June 2018 - Cyclomics obtains Take Off grant from the Dutch Organisation for Scientific Research.
Cyclomics and the University Medical Center Utrecht obtained 50.000 EUR in funding for further technical development and evaluation of their highly accurate mutation detection technology, which is based on proprietary DNA concatemerization technology and novel bioinformatics algorithms for mutation detection...
Cyclomics wins the Venture Challenge
November 2017 - Following a successful Health Holland Venture Challenge coaching program, involving the preparation of a business plan and a slide deck, Cyclomics participated into a pitch contest in front of a jury consisting of seasoned biotech entrepreneurs and experts. After a long deliberation of the jury, the winners were announced two weeks later at the Dutch Life Sciences conference at the Pivot Park in Oss. The combination of an excellent business plan and a crystal clear pitch and discussion session led to the unanimous decision of the jury to declare Cyclomics as the winners of the Health Holland Venture Challenge fall 2017, thereby winning a prize of 25.000 EUR. The Cyclomics team participating in the Venture Challenge program consisted of founders Alessio Marcozzi, Jeroen de Ridder and Wigard Kloosterman, each working at the University Medical Center Utrecht, and Genoveva Heldens from the Utrecht University Tech Transfer Office...